( PREZISTA PREZISTA was developed by T...)New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV,Health

PREZISTA was developed by Tibotec Pharmaceuticals Ltd. and is marketed in the U.S. by Tibotec Therapeutics, a division of Ortho Biotech Products, L.P. In the European Union, Russia, Switzerland and other countries, PREZISTA is marketed by Tibotec, a division of Janssen-Cilag. In Canada, PREZISTA is marketed by Tibotec, a division of Janssen-Ortho Inc. Applications for approval of PREZISTA also have been submitted or are planned for submission in many other countries.

About Tibotec Therapeutics

Tibotec Therapeutics, a division of Ortho Biotech Products, L.P., headquartered in Bridgewater, N.J., is dedicated to delivering innovative virology therapeutics that help healthcare professionals address serious unmet needs in people living with HIV.

About Tibotec Pharmaceuticals Ltd.

Tibotec Pharmaceuticals Ltd., based in Cork, Ireland, is a pharmaceutical research and development company. The Company's main research and development facilities are in Mechelen, Belgium with offices in Yardley, PA. Tibotec is dedicated to the discovery and development of innovative HIV/AIDS drugs and anti-infectives for diseases of high unmet medical need.

Tibotec Pharmaceuticals is developing a Global Access Program to facilitate access to its antiretrovirals for patients living with HIV/AIDS in developing countries. The Global Access Program for PREZISTA includes access pricing, registration, medical education for appropriate use and voluntary licensing.

    1 Kaletra(R) (lopinavir/ritonavir) is a trademark owned by Abbott

    2 Aptivus(R) (tipranavir) is a trademark owned by Boehringer Ingelheim

      Pharmaceuticals, Inc.

    3 Fuzeon(R) (enfuvirtide) is a trademark owned by Roche


    Contacts:

    Pam Van Houten

    Office: (908) 541-4137

CONTACT: Pam Van Houten for Tibotec Therapeutics, +1-908-541-4137

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association
'"/>